Quidels QuickVue® Influenza A+B Test Now Available in the United States

Article

SAN DIEGO -- Quidel Corporation today announced that its new QuickVue Influenza test A+B has become available in the United States. The new, CLIA-waived QuickVue Influenza A+B test provides information to aid in the differential diagnosis of acute influenza type A or B. The test provides physicians with a fast, accurate, easy-to-use method for aiding in the differential diagnosis of acute influenza type A or B. Using a nasal swab or nasal/wash aspirate, the test is designed to deliver results in 10 minutes or less and require only 30 seconds of hands-on time. Test kits can be stored at room temperature and have a 24-month shelf life from manufacture date.

 

Source: Quidel Corporation

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.